The Medicon Valley Inhalation Consortium (MVIC) and Upperton Pharma Solutions have announced a collaboration “designed to provide pharmaceutical and biotech companies with a seamless, end-to-end solution spanning early discovery, formulation development, preclinical support, and clinical trial manufacturing.” Earlier this year, Upperton entered a strategic collaboration with Bespak to provide nasal drug development and manufacturing services through to commercial manufacturing.
According to the MVIC and Upperton announcement, the two companies will offer inhaled and nasal drug development services through to clinical trial supply. They cite MVIC’s expertise in formulation design, device optimization, preclinical testing, toxicology, and regulatory support and Upperton’s capabilities in formulation, spray drying, sterile manufacturing, scale-up, quality systems support, and clinical manufacturing.
MVIC CEO Mats Håkansson commented, “Our ambition is to simplify drug development for our customers by offering a seamless route from discovery and early development through clinical manufacturing. By combining MVIC’s scientific and project management expertise with Upperton’s world-class manufacturing and formulation capabilities, we can provide a highly efficient and coordinated development pathway that helps bring innovative medicines to patients faster.”
Upperton CEO Nikki Whitfield said, “We are delighted to collaborate with MVIC to create a more integrated offering for pharmaceutical innovators. Together, we can help clients move more efficiently from innovative concepts to clinical evaluation by combining scientific excellence with robust manufacturing expertise.”
Read the MVIC and Upperton Pharma Solutions press release





